These results further highlight FOXP3+ Tregs’ potential use in biomarker-guided diagnostics and are consistent with previous research showing decreased levels of these cells in patients with autoimmune or inflammatory disorders such as atopic dermatitis. This evidence concerns the gene FOXP3 and atopic eczema.